Can insulin signaling pathways be targeted to transport Aß out of the brain?

Frontiers in Aging Neuroscience

Volumn 7, Issue MAY, 2015, Pages

  Milene, Vandal ^a,b,c   Philippe, Bourassa ^a,b   Frédéric, Calon ^a,b,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN; INSULIN RECEPTOR;

AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INSULIN RESISTANCE; INSULIN RESPONSE; MENTAL PERFORMANCE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 84931272360     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2015.00114     Document Type: Article

References (184)

1. Abramowski, D., Wiederhold, K. H., Furrer, U., Jaton, A. L., Neuenschwander, A., Runser, M. J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., Stoeckli, M., Rueeger, H., Neumann, U., and Staufenbiel, M. (2008). Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 327, 411-424.
2. Alata, W., Ye, Y., St-Amour, I., Vandal, M., and Calon, F. (2015). Human apolipoprotein E varepsilon4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J Cereb Blood Flow Metab 35, 86-94.
3. Banks, W. A. (2004). The source of cerebral insulin. Eur J Pharmacol 490, 5-12.
4. Banks, W. A., Jaspan, J. B., Huang, W., and Kastin, A. J. (1997a). Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18, 1423-1429.
5. Banks, W. A., Jaspan, J. B., and Kastin, A. J. (1997b). Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 18, 1257-1262.
6. Banks, W. A., and Kastin, A. J. (1998). Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19, 883-889.
7. Banks, W. A., Kastin, A. J., and Pan, W. (1999). Uptake and degradation of blood-borne insulin by the olfactory bulb. Peptides 20, 373-378.
8. Banks, W. A., Owen, J. B., and Erickson, M. A. (2012). Insulin in the brain: there and back again. Pharmacol Ther 136, 82-93.
9. Barron, A. M., Rosario, E. R., Elteriefi, R., and Pike, C. J. (2013). Sex-specific effects of high fat diet on indices of metabolic syndrome in 3xTg-AD mice: implications for Alzheimer's disease. PLoS One 8, e78554.
10. Barten, D. M., Guss, V. L., Corsa, J. A., Loo, A., Hansel, S. B., Zheng, M., Munoz, B., Srinivasan, K., Wang, B., Robertson, B. J., Polson, C. T., Wang, J., Roberts, S. B., Hendrick, J. P., Anderson, J. J., Loy, J. K., Denton, R., Verdoorn, T. A., Smith, D. W., and Felsenstein, K. M. (2005). Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 312, 635-643.
11. Basak, J. M., Kim, J., Pyatkivskyy, Y., Wildsmith, K. R., Jiang, H., Parsadanian, M., Patterson, B. W., Bateman, R. J., and Holtzman, D. M. (2012). Measurement of apolipoprotein E and amyloid beta clearance rates in the mouse brain using bolus stable isotope labeling. Mol Neurodegener 7, 14.
12. Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., and Holtzman, D. M. (2006). Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12, 856-861.
13. Baura, G. D., Foster, D. M., Porte, D. J., Kahn, S. E., Bergman, R. N., Cobelli, C., and Schwartz, M. W. (1993). Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest 92, 1824-1830.
14. Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., Berk, B. C., and Zlokovic, B. V. (2012). Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512-516.
15. Bhaskar, V., Goldfine, I. D., Bedinger, D. H., Lau, A., Kuan, H. F., Gross, L. M., Handa, M., Maddux, B. A., Watson, S. R., Zhu, S., Narasimha, A. J., Levy, R., Webster, L., Wijesuriya, S. D., Liu, N., Wu, X., Chemla-Vogel, D., Tran, C., Lee, S. R., Wong, S., Wilcock, D., White, M.L., and Corbin, J. A. (2012). A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 61, 1263-1271.
16. Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., and Nawroth, P. P. (2005). Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83, 876-886.
17. Bird, T. D. (2005). Genetic factors in Alzheimer's disease. N Engl J Med 352, 862-864.
18. Blessed, G., Tomlinson, B. E., and Roth, M. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114, 797-811.
19. Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C. M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., Seeger, M., Levey, A. I., Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, D. L., Younkin, S. G., and Sisodia, S. S. (1996). Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
20. Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., and Fehm, H. L. (2002). Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5, 514-516.
21. Bourasset, F., Ouellet, M., Tremblay, C., Julien, C., Do, T. M., Oddo, S., LaFerla, F., and Calon, F. (2009). Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology 56, 808-813.
22. Braak, H., Braak, E., and Bohl, J. (1993). Staging of Alzheimer-related cortical destruction. Eur Neurol 33, 403-408.
23. Brundel, M., van den Berg, E., Reijmer, Y. D., de Bresser, J., Kappelle, L. J., and Biessels, G. J. (2012). Cerebral haemodynamics, cognition and brain volumes in patients with type 2 diabetes. J Diabetes Complications 26, 205-209.
24. Chetelat, G., La Joie, R., Villain, N., Perrotin, A., de La Sayette, V., Eustache, F., and Vandenberghe, R. (2013). Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin 2, 356-365.
25. Cirrito, J. R., Deane, R., Fagan, A. M., Spinner, M. L., Parsadanian, M., Finn, M. B., Jiang, H., Prior, J. L., Sagare, A., Bales, K. R., Paul, S. M., Zlokovic, B. V., Piwnica-Worms, D., and Holtzman, D. M. (2005). P-glycoprotein deficiency at the blood-brain barrier increases amyloidbeta deposition in an Alzheimer disease mouse model. J Clin Invest 115, 3285-3290.
26. Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., DeMattos, R. B., and Holtzman, D. M. (2003). In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23, 8844-8853.
27. Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., and Selkoe, D. J. (1997). Mutant presenilins of Alzheimer's disease increase production of 42- residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3, 67-72.
28. Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., and Craft, S. (2015). Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 44, 897-906.
29. Cornford, E. M., and Hyman, S. (2005). Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx 2, 27-43.
30. Craft, S., Baker, L. D., Montine, T. J., Minoshima, S., Watson, G. S., Claxton, A., Arbuckle, M., Callaghan, M., Tsai, E., Plymate, S. R., Green, P. S., Leverenz, J., Cross, D., and Gerton, B. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69, 29-38.
31. Cummings, J. L. (2004). Alzheimer's disease. N Engl J Med 351, 56-67.
32. Dash, S., Xiao, C., Morgantini, C., Koulajian, K., and Lewis, G. F. (2015). Intranasal insulin suppresses endogenous glucose production in humans compared with placebo in the presence of similar venous insulin concentrations. Diabetes 64, 766-774.
33. De Felice, F. G., and Ferreira, S. T. (2014). Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63, 2262-2272.
34. De Strooper, B. (2014). Lessons from a failed gamma-secretase Alzheimer trial. Cell 159, 721-726.
35. De Strooper, B., and Chavez Gutierrez, L. (2015). Learning by failing: ideas and concepts to tackle gamma-secretases in Alzheimer's disease and beyond. Annu Rev Pharmacol Toxicol 55, 419-437.
36. Deane, R., Bell, R. D., Sagare, A., and Zlokovic, B. V. (2009). Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8, 16-30.
37. Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A. M., Armstrong, D. L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D., and Zlokovic, B. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913.
38. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., and Zlokovic, B. V. (2008). apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118, 4002-4013.
39. Deane, R., Wu, Z., and Zlokovic, B. V. (2004). RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631.
40. Desjardins, M., Berti, R., Lefebvre, J., Dubeau, S., and Lesage, F. (2014). Aging-related differences in cerebral capillary blood flow in anesthetized rats. Neurobiol Aging 35, 1947-1955.
41. Dickson, D. W. (1997). Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging 18, S21-S26.
42. Do, T. M., Alata, W., Dodacki, A., Traversy, M. T., Chacun, H., Pradier, L., Scherrmann, J. M., Farinotti, R., Calon, F., and Bourasset, F. (2014). Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease. Neuropharmacology 81, 311-317.
43. Do, T. M., Noel-Hudson, M. S., Ribes, S., Besengez, C., Smirnova, M., Cisternino, S., Buyse, M., Calon, F., Chimini, G., Chacun, H., Scherrmann, J. M., Farinotti, R., and Bourasset, F. (2012). ABCG2- and ABCG4-mediated efflux of amyloid-beta peptide 1-40 at the mouse bloodbrain barrier. J Alzheimers Dis 30, 155-166.
44. Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., Hovanesian, V., and Stopa, E. G. (2006). RAGE, LRP- 1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112, 405-415.
45. Donkin, J. J., Stukas, S., Hirsch-Reinshagen, V., Namjoshi, D., Wilkinson, A., May, S., Chan, J., Fan, J., Collins, J., and Wellington, C. L. (2010). ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 285, 34144-34154.
46. Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., and Mohs, R. (2013). A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369, 341-350.
47. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J., and Younkin, S. (1996). Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713.
48. Duffy, K. R., and Pardridge, W. M. (1987). Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 420, 32-38.
49. Erickson, M. A., and Banks, W. A. (2013). Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 33, 1500-1513.
50. Farrall, A. J., and Wardlaw, J. M. (2009). Blood-brain barrier: ageing and microvascular disease-- systematic review and meta-analysis. Neurobiol Aging 30, 337-352.
51. Fernandez, A. M., and Torres-Aleman, I. (2012). The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 13, 225-239.
52. Forbes, J. M., Sourris, K. C., de Courten, M. P., Dougherty, S. L., Chand, V., Lyons, J. G., Bertovic, D., Coughlan, M. T., Schlaich, M. P., Soldatos, G., Cooper, M. E., Straznicky, N. E., Kingwell, B. A., and de Courten, B. (2014). Advanced glycation end products (AGEs) are crosssectionally associated with insulin secretion in healthy subjects. Amino Acids 46, 321-326.
53. Frank, H. J., Jankovic-Vokes, T., Pardridge, W. M., and Morris, W. L. (1985). Enhanced insulin binding to blood-brain barrier in vivo and to brain microvessels in vitro in newborn rabbits. Diabetes 34, 728-733.
54. Freiherr, J., Hallschmid, M., Frey, W. H., Brunner, Y. F., Chapman, C. D., Holscher, C., Craft, S., De Felice, F. G., and Benedict, C. (2013). Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27, 505-514.
55. Galasko, D., Bell, J., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C., Thomas, R. G., and Aisen, P. S. (2014). Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology 82, 1536-1542.
56. Gancheva, S., Koliaki, C., Bierwagen, A., Nowotny, P., Heni, M., Fritsche, A., Haring, H. U., Szendroedi, J., and Roden, M. (2015). Effects of intranasal insulin on hepatic fat accumulation and energy metabolism in humans. Diabetes
57. Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., and Pedersen, N. L. (2006). Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63, 168-174.
58. Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., and et, A. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
59. Goedert, M., and Spillantini, M. G. (2006). A century of Alzheimer's disease. Science 314, 777-781.
60. Golde, T. E., Schneider, L. S., and Koo, E. H. (2011). Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69, 203-213.
61. Grichisch, Y., Cavusoglu, M., Preissl, H., Uludag, K., Hallschmid, M., Birbaumer, N., Haring, H. U., Fritsche, A., and Veit, R. (2012). Differential effects of intranasal insulin and caffeine on cerebral blood flow. Hum Brain Mapp 33, 280-287.
62. Grundman, M., Dibernardo, A., Raghavan, N., Krams, M., and Yuen, E. (2013). 2012: A watershed year for Alzheimer's disease research. J Nutr Health Aging 17, 51-53.
63. Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
64. Hachiya, H. L., Halban, P. A., and King, G. L. (1988). Intracellular pathways of insulin transport across vascular endothelial cells. Am J Physiol 255, C459-C464.
65. Hallschmid, M., Benedict, C., Schultes, B., Perras, B., Fehm, H. L., Kern, W., and Born, J. (2008). Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 149, 79-83.
66. Hasselbalch, S. G., Knudsen, G. M., Videbaek, C., Pinborg, L. H., Schmidt, J. F., Holm, S., and Paulson, O. B. (1999). No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 48, 1915-1921.
67. Havrankova, J., Schmechel, D., Roth, J., and Brownstein, M. (1978). Identification of insulin in rat brain. Proc Natl Acad Sci U S A 75, 5737-5741.
68. Hennebelle, M., Plourde, M., Chouinard-Watkins, R., Castellano, C. A., Barberger-Gateau, P., and Cunnane, S. C. (2014). Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline. Proc Nutr Soc 73, 80-86.
69. Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C. V., Hof, P. R., and Pasinetti, G. M. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-904.
70. Holland, J. P., Liang, S. H., Rotstein, B. H., Collier, T. L., Stephenson, N. A., Greguric, I., and Vasdev, N. (2014). Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. J Labelled Comp Radiopharm 57, 323-331.
71. Hong, H., Liu, L. P., Liao, J. M., Wang, T. S., Ye, F. Y., Wu, J., Wang, Y. Y., Wang, Y., Li, Y. Q., Long, Y., and Xia, Y. Z. (2009). Downregulation of LRP1 [correction of LPR1] at the bloodbrain barrier in streptozotocin-induced diabetic mice. Neuropharmacology 56, 1054-1059.
72. Janson, J., Laedtke, T., Parisi, J. E., O'Brien, P., Petersen, R. C., and Butler, P. C. (2004). Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481.
73. Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jonsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., and Stefansson, K. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.
74. Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Emond, V., Julien, P., and Calon, F. (2010). High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging 31, 1516-1531.
75. Kadir, A., Marutle, A., Gonzalez, D., Scholl, M., Almkvist, O., Mousavi, M., Mustafiz, T., Darreh-Shori, T., Nennesmo, I., and Nordberg, A. (2011). Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 134, 301-317.
76. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., and Malinow, R. (2003). APP processing and synaptic function. Neuron 37, 925-937.
77. Karczewska-Kupczewska, M., Lelental, N., Adamska, A., Nikolajuk, A., Kowalska, I., Gorska, M., Zimmermann, R., Kornhuber, J., Straczkowski, M., and Lewczuk, P. (2013). The influence of insulin infusion on the metabolism of amyloid beta peptides in plasma. Alzheimers Dement 9, 400-405.
78. Karran, E., Mercken, M., and De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
79. Kastin, A. J., and Akerstrom, V. (2001). Glucose and insulin increase the transport of leptin through the blood-brain barrier in normal mice but not in streptozotocin-diabetic mice. Neuroendocrinology 73, 237-242.
80. Katakam, P. V., Domoki, F., Lenti, L., Gaspar, T., Institoris, A., Snipes, J. A., and Busija, D. W. (2009). Cerebrovascular responses to insulin in rats. J Cereb Blood Flow Metab 29, 1955-1967.
81. Kennan, R. P., Takahashi, K., Pan, C., Shamoon, H., and Pan, J. W. (2005). Human cerebral blood flow and metabolism in acute insulin-induced hypoglycemia. J Cereb Blood Flow Metab 25, 527-534.
82. Kerr, D., Stanley, J. C., Barron, M., Thomas, R., Leatherdale, B. A., and Pickard, J. (1993). Symmetry of cerebral blood flow and cognitive responses to hypoglycaemia in humans. Diabetologia 36, 73-78.
83. Ketterer, C., Tschritter, O., Preissl, H., Heni, M., Haring, H. U., and Fritsche, A. (2011). Insulin sensitivity of the human brain. Diabetes Res Clin Pract 93 Suppl 1, S47-S51.
84. Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., and Holtzman, D. M. (2009). Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64, 632-644.
85. King, G. L., and Johnson, S. M. (1985). Receptor-mediated transport of insulin across endothelial cells. Science 227, 1583-1586.
86. Kleinridders, A., Ferris, H. A., Cai, W., and Kahn, C. R. (2014). Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63, 2232-2243.
87. Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., McDonald, W. C., Braak, H., and Petersen, R. C. (2003). Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62, 1087-1095.
88. Kondo, M., Shiono, M., Itoh, G., Takei, N., Matsushima, T., Maeda, M., Taru, H., Hata, S., Yamamoto, T., Saito, Y., and Suzuki, T. (2010). Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain. Mol Neurodegener 5, 35.
89. Kress, B. T., Iliff, J. J., Xia, M., Wang, M., Wei, H. S., Zeppenfeld, D., Xie, L., Kang, H., Xu, Q., Liew, J. A., Plog, B. A., Ding, F., Deane, R., and Nedergaard, M. (2014). Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 76, 845-861.
90. Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., Cascorbi, I., Walker, L. C., Kroemer, H. K., Warzok, R. W., and Vogelgesang, S. (2007). MDR1-PGlycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17, 347-353.
91. Kulstad, J. J., Green, P. S., Cook, D. G., Watson, G. S., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Rhoads, K., Mehta, P. D., and Craft, S. (2006). Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 66, 1506-1510.
92. Laatsch, A., Merkel, M., Talmud, P. J., Grewal, T., Beisiegel, U., and Heeren, J. (2009). Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis 204, 105-111.
93. Lane, R. F., Shineman, D. W., Steele, J. W., Lee, L. B., and Fillit, H. M. (2012). Beyond amyloid: the future of therapeutics for Alzheimer's disease. Adv Pharmacol 64, 213-271.
94. Li, H., Guo, Q., Inoue, T., Polito, V. A., Tabuchi, K., Hammer, R. E., Pautler, R. G., Taffet, G. E., and Zheng, H. (2014). Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener 9, 28.
95. Liu, L., and Liu, X. D. (2014). Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol 5, 273.
96. Liu, Y. H., Giunta, B., Zhou, H. D., Tan, J., and Wang, Y. J. (2012). Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol 8, 465-469.
97. Maesako, M., Uemura, K., Iwata, A., Kubota, M., Watanabe, K., Uemura, M., Noda, Y., Asada-Utsugi, M., Kihara, T., Takahashi, R., Shimohama, S., and Kinoshita, A. (2013). Continuation of exercise is necessary to inhibit high fat diet-induced beta-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. PLoS One 8, e72796.
98. Margolis, R. U., and Altszuler, N. (1967). Insulin in the cerebrospinal fluid. Nature 215, 1375-1376.
99. Mehta, D. C., Short, J. L., and Nicolazzo, J. A. (2013). Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease. Pharm Res 30, 2868-2879.
100. Michaud, J. P., Bellavance, M. A., Prefontaine, P., and Rivest, S. (2013). Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell Rep 5, 646-653.
101. Miller, D. W., Keller, B. T., and Borchardt, R. T. (1994). Identification and distribution of insulin receptors on cultured bovine brain microvessel endothelial cells: possible function in insulin processing in the blood-brain barrier. J Cell Physiol 161, 333-341.
102. Miller, M. C., Tavares, R., Johanson, C. E., Hovanesian, V., Donahue, J. E., Gonzalez, L., Silverberg, G. D., and Stopa, E. G. (2008). Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 1230, 273-280.
103. Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., van Belle, G., and Berg, L. (1991). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
104. Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., Harrington, M. G., Chui, H. C., Law, M., and Zlokovic, B. V. (2015). Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296-302.
105. Mori, T., Koyama, N., Segawa, T., Maeda, M., Maruyama, N., Kinoshita, N., Hou, H., Tan, J., and Town, T. (2014). Methylene blue modulates beta-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. J Biol Chem 289, 30303-30317.
106. Mormino, E. C. (2014). The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations. Neuropsychol Rev 24, 300-312.
107. Morris, G. P., Clark, I. A., and Vissel, B. (2014). Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun 2, 135.
108. Morris, M. C. (2009). The role of nutrition in Alzheimer's disease: epidemiological evidence. Eur J Neurol 16 Suppl 1, 1-7.
109. Morris, M. C., and Tangney, C. C. (2014). Dietary fat composition and dementia risk. Neurobiol Aging 35 Suppl 2, S59-S64.
110. Mullane, K., and Williams, M. (2013). Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 85, 289-305.
111. Niswender, K. D. (2011). Basal insulin: physiology, pharmacology, and clinical implications. Postgrad Med 123, 17-26.
112. Novak, V., Last, D., Alsop, D. C., Abduljalil, A. M., Hu, K., Lepicovsky, L., Cavallerano, J., and Lipsitz, L. A. (2006). Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes. Diabetes Care 29, 1529-1534.
113. Novak, V., Zhao, P., Manor, B., Sejdic, E., Alsop, D., Abduljalil, A., Roberson, P. K., Munshi, M., and Novak, P. (2011). Adhesion molecules, altered vasoreactivity, and brain atrophy in type 2 diabetes. Diabetes Care 34, 2438-2441.
114. Nugent, S., Castellano, C. A., Goffaux, P., Whittingstall, K., Lepage, M., Paquet, N., Bocti, C., Fulop, T., and Cunnane, S. C. (2014). Glucose hypometabolism is highly localized, but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults. Am J Physiol Endocrinol Metab 306, E1315-E1321.
115. Oldendorf, W. H. (1977). The blood-brain barrier. Exp Eye Res 25 Suppl, 177-190.
116. Oudegeest-Sander, M. H., van Beek, A. H., Abbink, K., Olde Rikkert, M. G., Hopman, M. T., and Claassen, J. A. (2014). Assessment of dynamic cerebral autoregulation and cerebrovascular CO2 reactivity in ageing by measurements of cerebral blood flow and cortical oxygenation. Exp Physiol 99, 586-598.
117. Ouwens, D. M., van Duinkerken, E., Schoonenboom, S. N., Herzfeld de Wiza, D., Klein, M., van Golen, L., Pouwels, P. J., Barkhof, F., Moll, A. C., Snoek, F. J., Teunissen, C. E., Scheltens, P., and Diamant, M. (2014). Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middleaged patients with type 1 diabetes. Diabetologia 57, 2208-2214.
118. Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hagerstrom, D., Wollmer, P., Minthon, L., and Hansson, O. (2014). Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a crossvalidation study against amyloid positron emission tomography. JAMA Neurol 71, 1282-1289.
119. Pandini, G., Pace, V., Copani, A., Squatrito, S., Milardi, D., and Vigneri, R. (2013). Insulin has multiple antiamyloidogenic effects on human neuronal cells. Endocrinology 154, 375-387.
120. Pardridge, W. M. (1986). Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev 7, 314-330.
121. Pardridge, W. M. (2011). Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 8, 7.
122. Paul, J., Strickland, S., and Melchor, J. P. (2007). Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204, 1999-2008.
123. Perry, G., Nunomura, A., Raina, A. K., and Smith, M. A. (2000). Amyloid-beta junkies. Lancet 355(9205), 757.
124. Plata-Salaman, C. R. (1991). Insulin in the cerebrospinal fluid. Neurosci Biobehav Rev 15, 243-258.
125. Pollock, R. F., Erny-Albrecht, K. M., Kalsekar, A., Bruhn, D., and Valentine, W. J. (2011). Longacting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. Curr Diabetes Rev 7, 61-74.
126. Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., Yarasheski, K. E., Holtzman, D. M., Morris, J. C., Benzinger, T.L., and Bateman, R. J. (2013). Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 5, 189ra77.
127. Powers, W. J., Hirsch, I. B., and Cryer, P. E. (1996). Effect of stepped hypoglycemia on regional cerebral blood flow response to physiological brain activation. Am J Physiol 270, H554-H559.
128. Preston, S. D., Steart, P. V., Wilkinson, A., Nicoll, J. A., and Weller, R. O. (2003). Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 29, 106-117.
129. Price, J. L., McKeel, D. W. J., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., Smith, C. D., Davis, D. G., Schmitt, F. A., Markesbery, W. R., Kaye, J., Kurlan, R., Hulette, C., Kurland, B. F., Higdon, R., Kukull, W., and Morris, J. C. (2009). Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30, 1026-1036.
130. Pujadas, L., Rossi, D., Andres, R., Teixeira, C. M., Serra-Vidal, B., Parcerisas, A., Maldonado, R., Giralt, E., Carulla, N., and Soriano, E. (2014). Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer's disease. Nat Commun 5, 3443.
131. Ramos-Rodriguez, J. J., Ortiz-Barajas, O., Gamero-Carrasco, C., de la Rosa, P. R., Infante-Garcia, C., Zopeque-Garcia, N., Lechuga-Sancho, A. M., and Garcia-Alloza, M. (2014). Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice. Psychoneuroendocrinology 48, 123-135.
132. Reger, M. A., Watson, G. S., Frey, W. H., Baker, L. D., Cholerton, B., Keeling, M. L., Belongia, D. A., Fishel, M. A., Plymate, S. R., Schellenberg, G. D., Cherrier, M. M., and Craft, S. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27, 451-458.
133. Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Cherrier, M. M., Schellenberg, G. D., Frey, W. H., and Craft, S. (2008). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memoryimpaired older adults. J Alzheimers Dis 13, 323-331.
134. Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., and Hardy, J. (2004). Functional brain abnormalities in young adults at genetic risk for lateonset Alzheimer's dementia. Proc Natl Acad Sci U S A 101, 284-289.
135. Rentz, D. M., Locascio, J. J., Becker, J. A., Moran, E. K., Eng, E., Buckner, R. L., Sperling, R. A., and Johnson, K. A. (2010). Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67, 353-364.
136. Roberson, E. D., and Mucke, L. (2006). 100 years and counting: prospects for defeating Alzheimer's disease. Science 314, 781-784.
137. Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller-Thomas, M. M., Moran, C. J., Cross, D. T., Derdeyn, C. P., and Bateman, R. J. (2014). Amyloid-beta efflux from the central nervous system into the plasma. Ann Neurol 76, 837-844.
138. Robinson, S. R., Bishop, G. M., Lee, H. G., and Munch, G. (2004). Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25, 609-615.
139. Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., and et al. (1995). Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778.
140. Rusinek, H., Ha, J., Yau, P. L., Storey, P., Tirsi, A., Tsui, W. H., Frosch, O., Azova, S., and Convit, A. (2015). Cerebral perfusion in insulin resistance and type 2 diabetes. J Cereb Blood Flow Metab 35, 95-102.
141. Sagare, A. P., Bell, R. D., and Zlokovic, B. V. (2012). Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2
142. Saito, S., and Ihara, M. (2014). New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci 6, 290
143. Salem, N. J., Vandal, M., and Calon, F. (2015). The benefit of docosahexaenoic acid for the adult brain in aging and dementia. Prostaglandins Leukot Essent Fatty Acids 92, 15-22.
144. Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A. G., Greenberg, B. D., Siman, R., and Scott, R. W. (1998). Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18, 1743-1752.
145. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., and Younkin, S. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2, 864-870.
146. Schilling, T. M., Ferreira de Sa, D. S., Westerhausen, R., Strelzyk, F., Larra, M. F., Hallschmid, M., Savaskan, E., Oitzl, M. S., Busch, H. P., Naumann, E., and Schachinger, H. (2014). Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation. Hum Brain Mapp 35, 1944-1956.
147. Schley, D., Carare-Nnadi, R., Please, C. P., Perry, V. H., and Weller, R. O. (2006). Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol 238, 962-974.
148. Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2000). The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498, 99-111.
149. Selkoe, D. J. (2001). Clearing the brain's amyloid cobwebs. Neuron 32, 177-180.
150. Selkoe, D. J. (2011). Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17, 1060-1065.
151. Serrano-Pozo, A., Frosch, M. P., Masliah, E., and Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189.
152. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J. F., Bruni, A. C., Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R. J., Wasco, W., Da Silva, H. A., Haines, J. L., Perkicak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., Rommens, J. M., and St George-Hyslop, P. H. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
153. Shiiki, T., Ohtsuki, S., Kurihara, A., Naganuma, H., Nishimura, K., Tachikawa, M., Hosoya, K., and Terasaki, T. (2004). Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 24, 9632-9637.
154. Skoog, I., Wallin, A., Fredman, P., Hesse, C., Aevarsson, O., Karlsson, I., Gottfries, C. G., and Blennow, K. (1998). A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 50, 966-971.
155. Son, S. M., Song, H., Byun, J., Park, K. S., Jang, H. C., Park, Y. J., and Mook-Jung, I. (2012). Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. Diabetes 61, 3126- 3138.
156. St George-Hyslop, P. H. (2000). Genetic factors in the genesis of Alzheimer's disease. Ann N Y Acad Sci 924, 1-7.
157. Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., and de la Monte, S. M. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
158. Stern, Y. (2012). Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 11, 1006- 1012.
159. Strazielle, N., and Ghersi-Egea, J. F. (2013). Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm 10, 1473-1491.
160. Stukas, S., Robert, J., and Wellington, C. L. (2014). High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. Cell Metab 19, 574-591.
161. Sun, Y. N., Liu, L. B., Xue, Y. X., and Wang, P. (2015). Effects of insulin combined with idebenone on blood-brain barrier permeability in diabetic rats. J Neurosci Res 93, 666-677.
162. Tagliamonte, A., DeMontis, M. G., Olianas, M., Onali, P. L., and Gessa, G. L. (1976). Possible role of insulin in the transport of tyrosine and tryptophan from blood to brain. Adv Exp Med Biol 69, 89-94.
163. Taheri, S., Gasparovic, C., Shah, N. J., and Rosenberg, G. A. (2011). Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping. Magn Reson Med 65, 1036-1042.
164. Tai, L. M., Loughlin, A. J., Male, D. K., and Romero, I. A. (2009). P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 29, 1079-1083.
165. Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., and Arnold, S. E. (2012). Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
166. Tallroth, G., Ryding, E., and Agardh, C. D. (1993). The influence of hypoglycaemia on regional cerebral blood flow and cerebral volume in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36, 530-535.
167. Tayeb, H. O., Yang, H. D., Price, B. H., and Tarazi, F. I. (2012). Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 134, 8-25.
168. Tennant, K. A., and Brown, C. E. (2013). Diabetes augments in vivo microvascular blood flow dynamics after stroke. J Neurosci 33, 19194-19204.
169. Tremblay, C., Pilote, M., Phivilay, A., Emond, V., Bennett, D. A., and Calon, F. (2007). Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 12, 377-390.
170. Tremblay, C., St-Amour, I., Schneider, J., Bennett, D. A., and Calon, F. (2011). Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 70, 788-798.
171. Unger, J., McNeill, T. H., Moxley, R. T., White, M., Moss, A., and Livingston, J. N. (1989). Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 31, 143-157.
172. Vandal, M., Alata, W., Tremblay, C., Rioux-Perreault, C., Salem, N. J., Calon, F., and Plourde, M. (2014a). Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem 129, 516-526.
173. Vandal, M., White, P. J., Tremblay, C., St-Amour, I., Chevrier, G., Emond, V., Lefrancois, D., Virgili, J., Planel, E., Giguere, Y., Marette, A., and Calon, F. (2014b). Insulin reverses the highfat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease. Diabetes 63, 4291-4301.
174. Wang, H., Golob, E. J., and Su, M. Y. (2006). Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls. J Magn Reson Imaging 24, 695-700.
175. Wang, X., Yu, S., Gao, S. J., Hu, J. P., Wang, Y., and Liu, H. X. (2014). Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer's disease. Neuro Endocrinol Lett 35, 224-229.
176. Watson, G. S., Peskind, E. R., Asthana, S., Purganan, K., Wait, C., Chapman, D., Schwartz, M. W., Plymate, S., and Craft, S. (2003). Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60, 1899-1903.
177. Weiss, N., Miller, F., Cazaubon, S., and Couraud, P. O. (2009). The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788, 842-857.
178. Weller, R. O., Djuanda, E., Yow, H. Y., and Carare, R. O. (2009). Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117, 1-14.
179. Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., and Landreth, G. E. (2013). Evidence for impaired amyloid beta clearance in Alzheimer's disease. Alzheimers Res Ther 5, 33.
180. Witt, K. A., Huber, J. D., Egleton, R. D., and Davis, T. P. (2000). Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect. J Pharmacol Exp Ther 295, 972-978.
181. Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O'Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., Takano, T., Deane, R., and Nedergaard, M. (2013). Sleep drives metabolite clearance from the adult brain. Science 342, 373-377.
182. Yu, Y., Kastin, A. J., and Pan, W. (2006). Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier. Endocrinology 147, 2611-2615.
183. Zemva, J., and Schubert, M. (2014). The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications. CNS Neurol Disord Drug Targets 13, 322-337.
184. Zhang, Y., and Lee, D. H. (2011). Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist 17, 163-173.